单价XBB.1.5 mRNA新冠疫苗对JN.1的中和抗体应答优于二价BA.1和BA.5疫苗
研究比较接种三款Moderna mRNA新冠疫苗后1个月对JN.1的中和抗体应答。XBB.1.5、BA.1和BA.4-5疫苗受者分别有37、30和30份血清。JN.1特异性中和滴度的几何平均倍数上升(GMFR)分别为27、10.1和8.77;BA.1组调整后应答低64%(几何平均比[GMR]=0.36,95%CI:0.21-0.6),BA.4-5组低75%(GMR=0.25,95%CI:0.15-0.43)。
要点
- 接种XBB.1.5疫苗后JN.1中和滴度GMFR为27(95%CI:17-43.1)。
- BA.1组JN.1应答较XBB.1.5组低64%(GMR=0.36,95%CI:0.21-0.6)。
- BA.4-5组JN.1应答较XBB.1.5组低75%(GMR=0.25,95%CI:0.15-0.43)。
核心结论
- XBB.1.5疫苗接种相比其他新冠疫苗最可能对JN.1产生更好的有效性。
研究设计与样本
- 比较接种三款可用Moderna mRNA新冠疫苗后1个月对JN.1的中和抗体应答。
- XBB.1.5、BA.1和BA.4-5疫苗受者分别有37、30和30份血清。
- 检测抗RBD IgG和JN.1特异性中和抗体水平。
主要发现
- JN.1特异性中和滴度GMFR:XBB.1.5组27(95%CI:17-43.1),BA.1组10.1(95%CI:6.48-15.7),BA.4-5组8.77(95%CI:5.69-13.5)。
- BA.1组调整后应答较XBB.1.5组低64%(GMR=0.36,95%CI:0.21-0.6)。
- BA.4-5组应答较XBB.1.5组低75%(GMR=0.25,95%CI:0.15-0.43)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
JN.1, the dominating SARS-CoV-2 variant, is antigenically distinct from ancestral BA.1, BA.5 and XBB.1.5 variants, raising concern about effectiveness of updated COVID-19 vaccines. Here, we compared the neutralizing antibody response against JN.1, 1-month after receipt of the three available Moderna mRNA vaccines. Sera obtained from 37, 30 and 30 XBB.1.5, BA.1 and BA.4-5 -vaccine recipients, respectively, were tested for anti-RBD IgG and for JN-1 specific neutralizing antibody levels. Geometric mean fold rise (GMFR) in JN.1 specific neutralizing titers was 27 (95 % CI: 17-43.1), 10.1 (95 % CI: 6.48-15.7) and 8.77 (95 % CI: 5.69-13.5) following XBB.1.5, BA.1 and BA.4-5 vaccines, respectively, translating into a 64 % lower adjusted response (geometric mean ratio [GMR] = 0.36, 95 % CI: 0.21-0.6) in the BA.1 arm, and a 75 % lower response (GMR = 0.25, 95 % CI: 0.15-0.43) in the BA.4-5 arm. This suggests that XBB.1.5 vaccination will most likely, result in improved effectiveness against JN.1 compared with other COVID-19 vaccines.
引用
- Lustig Y, Barda N, Weiss-Ottolenghi Y, et al. Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines. Vaccine. 2024. PMID: 38806352. doi:10.1016/j.vaccine.2024.05.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。